The Insurance Landscape for Ketamine Therapy
One of the most frustrating aspects of pursuing ketamine therapy is navigating insurance coverage. The landscape is complicated, inconsistent, and often feels like it was designed to confuse rather than help. But understanding how coverage works — and where the opportunities lie — can save you thousands of dollars and significantly reduce the financial stress of treatment.
This guide breaks down the current state of insurance coverage for ketamine therapy, explains the difference between what is and is not typically covered, and gives you practical strategies for maximizing your benefits.
Understanding the Two Categories
The single most important distinction in ketamine insurance coverage is between FDA-approved Spravato (esketamine) and off-label generic ketamine.
Spravato (Esketamine Nasal Spray)
Spravato received FDA approval in 2019 for treatment-resistant depression and in 2020 for major depressive disorder with acute suicidal ideation or behavior. Because it has FDA approval for specific psychiatric indications, many insurance plans cover it — though coverage varies significantly.
What coverage typically looks like:
- Most major commercial insurance plans cover Spravato, though often with restrictions
- Medicare Part D generally covers Spravato
- Medicaid coverage varies by state but is expanding
- Prior authorization is almost always required
- You must meet the diagnostic criteria: treatment-resistant depression (failure of at least two adequate antidepressant trials) or MDD with suicidal ideation
- You must use it in conjunction with a newly initiated or ongoing oral antidepressant
- Treatment must occur at a REMS-certified healthcare setting
Typical out-of-pocket costs with insurance: $0 to $200 per session, depending on your plan's copay or coinsurance structure. The Janssen CarePath savings program can reduce copays to as low as $10 per session for commercially insured patients.
Generic Ketamine (IV, IM, Sublingual, Oral)
Generic ketamine used for depression, anxiety, PTSD, and other psychiatric conditions is prescribed off-label. The medication itself is inexpensive — often just a few dollars per dose — but the administration, monitoring, and provider fees are where the costs add up.
The coverage reality:
- Most insurance plans do not cover generic ketamine infusions or at-home sublingual programs for psychiatric indications
- The medication itself may be covered at a compounding pharmacy with a prescription, but this varies
- Some components of treatment may be billable — the initial psychiatric evaluation, vital sign monitoring, and follow-up visits can sometimes be coded and submitted to insurance
- A small but growing number of providers are finding ways to bill portions of IV ketamine treatment under medical supervision codes
The Prior Authorization Process
If you are pursuing Spravato or attempting to get any ketamine-related treatment covered, prior authorization is likely part of the process.
What Prior Authorization Involves
Prior authorization is your insurance company's way of confirming that a treatment is medically necessary before they agree to pay for it. Your provider submits a request that includes:
- Your diagnosis and diagnostic codes (ICD-10)
- Documentation of previous treatment failures (medications tried, doses, durations, and why they were inadequate)
- Clinical rationale for why ketamine or Spravato is appropriate
- Your current treatment plan
- Relevant clinical notes and assessment scores (PHQ-9, GAD-7, Columbia Suicide Severity Rating Scale)
Timeline
Prior authorization decisions typically take three to five business days for standard requests and 24 to 72 hours for urgent requests. Some insurance companies have expedited pathways for patients with suicidal ideation.
Tips for a Successful Prior Authorization
- Document everything thoroughly. The more detailed your treatment history, the stronger your case. Include specific medication names, doses, durations, and the specific reasons each was discontinued or deemed inadequate.
- Use standardized assessment scores. Objective measures like the PHQ-9 carry more weight than subjective descriptions alone.
- Have your provider write a strong letter of medical necessity. This letter should explain why standard treatments have failed and why ketamine therapy is the appropriate next step.
- Include peer-reviewed research. Attaching key studies that support ketamine for your specific diagnosis can strengthen the authorization request.
What to Do If You Are Denied
Insurance denials are common, but they are not the final word. You have the right to appeal, and appeals are often successful — particularly for Spravato.
The Appeals Process
Step 1: Understand the denial reason. Read the denial letter carefully. Common reasons include insufficient documentation of treatment failures, not meeting diagnostic criteria, or the treatment being considered experimental.
Step 2: Request a peer-to-peer review. Your provider can request a direct conversation with the insurance company's medical reviewer. This person-to-person discussion often resolves issues that paperwork alone cannot.
Step 3: File a formal internal appeal. Submit additional documentation addressing the specific denial reason. Include updated clinical notes, additional treatment history, and a revised letter of medical necessity.
Step 4: File an external appeal. If the internal appeal is denied, you have the right to an independent external review in most states. An external reviewer who is not affiliated with your insurance company will evaluate your case.
Step 5: Contact your state insurance commissioner. If you believe the denial is unjust, your state's insurance regulatory body can investigate and intervene.
Success Rates
Appeals for Spravato coverage are frequently successful, particularly when the denial was based on insufficient documentation that can be remedied. Persistence matters — some patients report going through two or three rounds of appeals before receiving approval.
Strategies to Reduce Out-of-Pocket Costs
For Spravato
- Janssen CarePath Savings Program: Eligible commercially insured patients can pay as little as $10 per session. Visit the Spravato website or ask your provider for enrollment details.
- Manufacturer Patient Assistance Programs: For uninsured or underinsured patients, Janssen offers assistance programs that may cover the cost of the medication itself.
- Medicare Extra Help: If you have Medicare and limited income, the Extra Help program can reduce prescription drug costs.
For Generic Ketamine
- Ask about superbills. Even if a clinic does not bill insurance directly, they can provide a superbill — a detailed receipt with medical codes — that you can submit to your insurance for potential out-of-network reimbursement.
- Use your out-of-network benefits. Many PPO plans offer out-of-network coverage at a reduced rate. If you have already met your out-of-network deductible, reimbursement can be substantial.
- Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). Ketamine therapy is generally considered a qualified medical expense. For more tips, see our guide on finding affordable ketamine treatment for HSA and FSA purposes. This lets you pay with pre-tax dollars, effectively reducing the cost by your marginal tax rate.
- Ask about payment plans. Many clinics offer interest-free payment plans that spread the cost over several months.
- Consider the total cost of inaction. This is not a financial strategy per se, but it is worth considering: the cost of untreated depression — in lost productivity, strained relationships, emergency room visits, and reduced quality of life — often exceeds the cost of treatment.
Billing Codes That Matter
Understanding the billing codes your provider uses can help you navigate the insurance process more effectively:
- 96365 — Intravenous infusion, initial (used for IV ketamine administration)
- 96366 — Intravenous infusion, additional hour
- 99213-99215 — Evaluation and management codes for follow-up visits
- 90792 — Psychiatric diagnostic evaluation (initial consultation)
- S0013 — Esketamine nasal spray (Spravato-specific code)
- J3490 — Unclassified drug (sometimes used for compounded ketamine)
Ask your provider which codes they use and verify with your insurance company whether those codes are covered under your plan.
The Coverage Landscape Is Changing
Insurance coverage for ketamine therapy is evolving. As clinical evidence continues to accumulate and more patients demonstrate positive outcomes, payers are gradually expanding coverage. Some forward-thinking employers are adding ketamine therapy to their mental health benefits, and a few insurance companies have begun pilot programs for generic ketamine coverage.
Advocacy organizations, patient groups, and professional societies are actively working to improve access. While the current situation is imperfect, the trajectory is moving toward broader coverage.
Your Next Steps
- Call your insurance company and ask specifically about coverage for Spravato and ketamine therapy
- Request a copy of your plan's formulary and mental health benefit summary
- Ask your provider about prior authorization and whether they have experience navigating the process with your specific insurer
- Explore manufacturer savings programs and patient assistance options
- Consider HSA/FSA eligibility and out-of-network reimbursement strategies
The financial aspect of ketamine therapy should not be a barrier to care. For a full cost breakdown by treatment type, see how much ketamine therapy costs. With the right information and a willingness to navigate the system, there are pathways to make treatment more affordable.
References
- SAMHSA: National Helpline — Free, confidential 24/7 referral and information service for mental health and substance use disorders
- Healthcare.gov — Federal health insurance marketplace for exploring coverage options
- FindTreatment.gov — SAMHSA treatment locator to find mental health and substance use treatment facilities
- Mayo Clinic: Treatment-Resistant Depression — Mayo Clinic information on treatment-resistant depression and available therapies including esketamine